Trial Profile
Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ERY-ASP (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors ERYtech Pharma
- 31 May 2020 Results assessing the prognostic and predictive value of circulating tumor DNA (ctDNA) in plasma samples of patients included in the eryaspase phase 2 trial presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 25 Nov 2019 According to an ERYtech Pharma media release, the company looks forward to confirm these results in the ongoing Phase 3 study (TRYbeCA1) which is now well underway internationally.
- 25 Nov 2019 Results published in the ERYtech Pharma Media Release.